Kymera Therapeutics Inc. (KYMR) News
Filter KYMR News Items
KYMR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KYMR News Highlights
- KYMR's 30 day story count now stands at 8.
- Over the past 15 days, the trend for KYMR's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- KT and DEC are the most mentioned tickers in articles about KYMR.
Latest KYMR News From Around the Web
Below are the latest news stories about KYMERA THERAPEUTICS INC that investors may wish to consider to help them evaluate KYMR as an investment opportunity.
Kymera Therapeutics Has Doubled in 2 Months, But Is the Upside Sustainable?Kymera Therapeutics is a clinical stage biopharmaceutical company focused on "discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system." The clinical stage business is expensive and risky, so let's check out a few charts and indicators for some guidance on the stock. The On-Balance-Volume (OBV) line has moved upwards since October telling me that buyers of KYMR have been more aggressive than sellers. |
12 Most Promising Cancer Stocks According to AnalystsIn this piece, we will take a look at the 12 most promising cancer stocks according to analysts. If you want to skip our overview of the latest trends in the cancer treatment sector, then you can take a look at the 5 Most Promising Cancer Stocks According to Analysts. The advent of technology and […] |
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 34% Share Price Surge Not Quite Adding UpThe Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) share price has done very well over the last month, posting an excellent... |
We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4Company to provide update on its emerging pipeline of high-value immunology programsWATERTOWN, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared webcast information for the virtual Immunology R&D Day that the Company will host on January 4, 2024, from 10:00 a.m. to 12:00 p.m. ET. The R&D Day will focus on the Company’ |
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual MeetingSTAT3 Degrader KT-333 showed early signs of antitumor activity across liquid and solid tumors, including major responses in cutaneous T-cell lymphoma (CTCL) and Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect demonstrated in tumor as well as blood KT-333 was generally well-tolerated with dose escalation continuing WATERTOWN, Mass., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new |
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same. |
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from SanofiAtopic Dermatitis (AD) trial is the second KT-474 Phase 2 clinical trial to begin enrolling patients this quarter following trial in Hidradenitis Suppurativa (HS) Topline Phase 2 data from both the AD and HS trials expected in the first half of 2025 WATERTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that |
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature MedicineKT-474 showed evidence of robust target degradation and pathway inhibition with a favorable safety profile in healthy volunteers and patients Trial showed encouraging impact on disease burden and symptoms in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD), with a systemic anti-inflammatory effect observed in patients with moderate-to-severe disease Study is first published clinical trial using a heterobifunctional degrader Kymera’s partner Sanofi conducting Phase 2 clinical trials of KT |
BIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics IncOn November 3, 2023, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio), a prominent investment firm, increased its holdings in Kymera Therapeutics Inc (NASDAQ:KYMR), a leading biotechnology company based in the USA. This article provides an in-depth analysis of the transaction, the profiles of the guru and the traded company, and the potential implications for value investors. The firm added 414,105 shares of Kymera Therapeutics Inc to its portfolio at a traded price of $14.27 per share. |